ATE250940T1 - Zielgerichte ortsspezifische arzneimittelzusammensetzungen und verwendungen - Google Patents
Zielgerichte ortsspezifische arzneimittelzusammensetzungen und verwendungenInfo
- Publication number
- ATE250940T1 ATE250940T1 AT99933960T AT99933960T ATE250940T1 AT E250940 T1 ATE250940 T1 AT E250940T1 AT 99933960 T AT99933960 T AT 99933960T AT 99933960 T AT99933960 T AT 99933960T AT E250940 T1 ATE250940 T1 AT E250940T1
- Authority
- AT
- Austria
- Prior art keywords
- microbubbles
- therapeutic
- site
- delivery
- specific drug
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000002604 ultrasonography Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Nanotechnology (AREA)
- Radiology & Medical Imaging (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/114,399 US6245747B1 (en) | 1996-03-12 | 1998-07-13 | Targeted site specific antisense oligodeoxynucleotide delivery method |
US09/118,168 US6117858A (en) | 1996-06-28 | 1998-07-17 | Compositions and methods for altering the biodistribution of biological agents |
PCT/US1999/015801 WO2000002588A1 (en) | 1998-07-13 | 1999-07-13 | Targeted site specific drug delivery compositions and method of use |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE250940T1 true ATE250940T1 (de) | 2003-10-15 |
Family
ID=26812136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99933960T ATE250940T1 (de) | 1998-07-13 | 1999-07-13 | Zielgerichte ortsspezifische arzneimittelzusammensetzungen und verwendungen |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1094843B1 (de) |
JP (1) | JP2002520298A (de) |
AT (1) | ATE250940T1 (de) |
AU (1) | AU743695B2 (de) |
CA (1) | CA2337361C (de) |
DE (1) | DE69911777T2 (de) |
WO (1) | WO2000002588A1 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2408746C (en) * | 2000-05-17 | 2010-09-21 | Patrick L. Iversen | Antisense phosporodiamidate morpholino oligonucleotide inhibition of cytochrome p450 to modulate drug pharmacokinetics |
JP2002145784A (ja) * | 2000-11-10 | 2002-05-22 | Ryuichi Morishita | 生物学的活性薬剤導入組成物およびその使用方法 |
DE10108798A1 (de) * | 2001-02-19 | 2002-09-26 | Laser & Med Tech Gmbh | Verfahren und Vorrichtung zur ultraschallgestützten transmembranen Medikamentenapplikation in vivo |
WO2003080123A1 (fr) * | 2002-03-22 | 2003-10-02 | Anges Mg, Inc. | Compositions delivrant un medicament biologiquement actif, et procede d'utilisation |
US20030207907A1 (en) | 2002-05-03 | 2003-11-06 | Iversen Patrick L. | Delivery of microparticle-conjugated drugs for inhibition of stenosis |
US7754238B2 (en) | 2002-05-03 | 2010-07-13 | Avi Biopharma, Inc. | Delivery of microparticle-conjugated drugs for inhibition of stenosis |
DE10223196B4 (de) | 2002-05-24 | 2004-05-13 | Dornier Medtech Systems Gmbh | Verfahren und Einrichtung zum Transferieren von Molekülen in Zellen |
ES2351976T3 (es) | 2003-04-29 | 2011-02-14 | Avi Biopharma, Inc. | Composiciones para mejorar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células. |
DE602005019367D1 (de) | 2004-12-15 | 2010-04-01 | Dornier Medtech Systems Gmbh | Verbesserte Zelltherapie und Gewebsregeneration mittels Stosswellen bei Patienten mit kardiovaskulären and neurologischen Krankheiten |
WO2007028981A1 (en) * | 2005-09-08 | 2007-03-15 | University Of Dundee | Apparatus and method for sonoporation |
SI2735568T1 (en) | 2006-05-10 | 2018-01-31 | Sarepta Therapeutics, Inc. | Analogues of the oligonucleotide, with cationic links between subunits |
WO2009005793A2 (en) | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
EP2231230A4 (de) | 2007-12-21 | 2013-01-23 | Carticept Medical Inc | Gelenkinjektionssystem |
US8545440B2 (en) | 2007-12-21 | 2013-10-01 | Carticept Medical, Inc. | Injection system for delivering multiple fluids within the anatomy |
US9044542B2 (en) | 2007-12-21 | 2015-06-02 | Carticept Medical, Inc. | Imaging-guided anesthesia injection systems and methods |
WO2014117232A1 (pt) * | 2013-02-04 | 2014-08-07 | Farret Neto Abdo | Preparação medicinal sob a forma de espuma para a liberação prolongada de medicamentos e sistema para obtenção da preparação medicinal |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6088613A (en) * | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US5567415A (en) * | 1993-05-12 | 1996-10-22 | The Board Of Regents Of The University Of Nebraska | Ultrasound contrast agents and methods for their manufacture and use |
GB9502065D0 (en) * | 1995-02-02 | 1995-03-22 | Nycomed Imaging As | Contrast media |
US5997898A (en) * | 1995-06-06 | 1999-12-07 | Imarx Pharmaceutical Corp. | Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery |
WO1997033474A1 (en) * | 1996-03-12 | 1997-09-18 | Board Of Regents Of The University Of Nebraska | Targeted site specific drug delivery compositions and method of use |
US5849727A (en) * | 1996-06-28 | 1998-12-15 | Board Of Regents Of The University Of Nebraska | Compositions and methods for altering the biodistribution of biological agents |
WO1998018498A2 (en) * | 1996-10-28 | 1998-05-07 | Marsden, John, Christopher | Improvements in or relating to diagnostic/therapeutic agents |
-
1999
- 1999-07-13 CA CA2337361A patent/CA2337361C/en not_active Expired - Lifetime
- 1999-07-13 JP JP2000558847A patent/JP2002520298A/ja active Pending
- 1999-07-13 AT AT99933960T patent/ATE250940T1/de active
- 1999-07-13 DE DE69911777T patent/DE69911777T2/de not_active Expired - Lifetime
- 1999-07-13 WO PCT/US1999/015801 patent/WO2000002588A1/en active IP Right Grant
- 1999-07-13 EP EP99933960A patent/EP1094843B1/de not_active Expired - Lifetime
- 1999-07-13 AU AU49899/99A patent/AU743695B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
CA2337361C (en) | 2010-11-16 |
DE69911777T2 (de) | 2004-04-29 |
WO2000002588A1 (en) | 2000-01-20 |
DE69911777D1 (de) | 2003-11-06 |
AU743695B2 (en) | 2002-01-31 |
AU4989999A (en) | 2000-02-01 |
CA2337361A1 (en) | 2000-01-20 |
EP1094843B1 (de) | 2003-10-01 |
EP1094843A1 (de) | 2001-05-02 |
JP2002520298A (ja) | 2002-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE250940T1 (de) | Zielgerichte ortsspezifische arzneimittelzusammensetzungen und verwendungen | |
ATE264114T1 (de) | Zyklodexrinpolymere zum gebrauch als medikamententräger | |
BRPI0607549A2 (pt) | sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos | |
MY149623A (en) | Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation | |
DE60028415D1 (de) | Methode und zusammensetzungen für verbesserte abgabevorrichtungen | |
EA200600696A1 (ru) | Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств | |
DE60038183D1 (de) | Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe | |
BR9917089A (pt) | Composições e métodos para distribuição mucosal | |
ATE391708T1 (de) | Verbindungen und gemische zur verabreichung eines aktiven agens | |
DE60220408D1 (de) | Sequenzielles arzneimittelabgabesystem | |
NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
BRPI0416260A (pt) | método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica | |
MXPA05002814A (es) | Formulacion para agentes lipofilicos. | |
BRPI0415007A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
MY167123A (en) | Conveniently implantable sustained release drug compositions | |
DE69931930D1 (de) | Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen | |
MXPA02010801A (es) | Agentes diagnosticos, de representacion y terapeuticos cationicos asociados con sitios vasculares activados. | |
TR200101867T2 (tr) | CCR5 modülatörleri olarak piperidinler | |
BRPI0415971A (pt) | método para tratar, prevenir ou controlar degeneração macular, e, composição farmacêutica | |
MXPA05003591A (es) | Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos. | |
NZ527157A (en) | Compositions for delivering bisphosphonates | |
BRPI0407897A (pt) | derivados de cianopiridina úteis no tratamento de cáncer e outros distúrbios | |
CY1107906T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου | |
MY140840A (en) | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | |
EP0888054A4 (de) | Zielortspezische medikamentverabreichungs-zusammensetzungen und verfahren zur anwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1094843 Country of ref document: EP |